Benefits of the Implantable Cardioverter-Defibrillator
Andrew E. Epstein, MD, FACC*
Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Major ICD Trials
Hazard ratios (vertical line) and 95% confidence intervals (horizontal lines) for death from any cause in the implantable cardioverter-defibrillator (ICD) group compared with the non-ICD group. *Includes only ICD and amiodarone patients from CASH. AVID = Antiarhythmics Versus Implantable Defibrillators trial; CABG = coronary artery bypass graft surgery; CASH = Cardiac Arrest Study Hamburg; CIDS = Canadian Implantable Defibrillator Study; DEFINITE = Defibrillator in Nonischemic Cardiomyopathy Treatment Evaluation trial; DINAMIT = Defibrillator in Acute Myocardial Infarction trial; EP = electrophysiological study; LVD = left ventricular dysfunction; LVEF = left ventricular ejection fraction; MADIT = Multicenter Automatic Defibrillator Implantation Trial; MI = myocardial infarction; NICM = nonischemic cardiomyopathy; NSVT = nonsustained ventricular tachycardia; PVC = premature ventricular complex; SAECG = signal-averaged electrocardiogram; SCD-HeFT = Sudden Cardiac Death in Heart Failure Trial.
|
|
|
